JMP Securities Maintains Market Outperform on Rhythm Pharmaceuticals, Raises Price Target to $135
Author: Benzinga Newsdesk | August 06, 2025 10:19am
JMP Securities analyst Jonathan Wolleben maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Market Outperform and raises the price target from $130 to $135.